Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| EVMN | 8-K | bearish | 7/10 | Evommune announced top-line results from its Phase 2b trial of EVO756 in chronic spontaneous urticaria (CSU). The 160-pa | Jun 29, 2026 |
| REPL | 8-K | bullish | 7/10 | Replimune reported fiscal Q4 2026 results with net loss of $73.7M, in line with expectations for a pre-revenue biotech. | Jun 29, 2026 |
| TNYA | 8-K | neutral | 2/10 | Tenaya Therapeutics announced the appointment of Eric Hyllengren as CFO, effective July 13, 2026, replacing interim CFO | Jun 29, 2026 |
| OPTH | 6-K | neutral | 4/10 | Optimi Health announced its third commercial psilocybin export to Australia, a shipment of 1,000 capsules for treatment- | Jun 29, 2026 |
| AKTX | PRESS-RELEASE | neutral | 3/10 | Akari Therapeutics announced the completion of its PIPE financing, consolidating the second and third closings into a si | Jun 29, 2026 |
| REPL | PRESS-RELEASE | bullish | 7/10 | Replimune reported a fiscal Q4 2026 EPS miss of -$0.77 vs -$0.72 consensus, a -6.9% surprise, with no revenue. The highl | Jun 29, 2026 |
| RDHL | 424B5 | bearish | 7/10 | RedHill Biopharma updated its ATM sales agreement shelf to allow sale of up to $2,128,000 in ADSs, supplementing prior s | Jun 29, 2026 |
| AGIO | PRESS-RELEASE | neutral | 1/10 | Agios Pharmaceuticals, Inc. announced it will host a conference call on July 30 to discuss its Q2 2026 results. | Jun 29, 2026 |
| DNTH | PRESS-RELEASE | bullish | 5/10 | Dianthus Therapeutics initiated the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis, building on p | Jun 29, 2026 |
| HCM | 6-K | neutral | 2/10 | HUTCHMED filed a routine blocklisting six-monthly return for its share option schemes, reporting an increase of 43.6 mil | Jun 29, 2026 |
| TAK | 6-K | neutral | 2/10 | Takeda filed a 6-K furnishing an English translation of its updated Articles of Incorporation, effective June 29, 2026. | Jun 29, 2026 |
| ENSC | EFFECT | bearish | 5/10 | Ensysce Biosciences' S-3 registration statement (resale of 1,300,000 shares by selling securityholders) became effective | Jun 29, 2026 |
| NNVC | EFFECT | bearish | 5/10 | NanoViricides' Form S-3 shelf registration became effective on June 26, 2026, allowing the company to offer up to $50 mi | Jun 29, 2026 |
| DCOY | 8-K | bearish | 7/10 | Decoy Therapeutics entered into a securities purchase agreement to raise approximately $3.5 million through a private pl | Jun 29, 2026 |
| NUVB | 424B5 | bearish | 6/10 | Nuvation Bio is issuing $250M of 0.75% convertible senior notes due 2032, with net proceeds of ~$241.2M. The offering is | Jun 29, 2026 |
| NAGE | S-3 | bearish | 6/10 | Niagen Bioscience filed a universal shelf registration statement (S-3) to offer up to $125M in securities (common stock, | Jun 29, 2026 |
| ZYME | PRESS-RELEASE | bullish | 7/10 | Zymeworks Inc. (ZYME) announced an agreement to acquire Theravance Biopharma (TBPH) for $17.00 per share, or approximate | Jun 29, 2026 |
| AMRX | PRESS-RELEASE | bullish | 5/10 | Zambon and Amneal announced that the CHMP adopted a positive opinion recommending EU marketing authorization for Hopledo | Jun 29, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio announced positive Phase 3 PROPEL 3 results for oral infigratinib in achondroplasia, published in NEJM and pre | Jun 28, 2026 |
| SYRE | CLUSTER | bearish | 7/10 | A massive insider selling cluster at Spyre Therapeutics (SYRE) saw $402M in open-market sales over four days, led by dir | Jun 26, 2026 |
| IMVT | CLUSTER | neutral | 2/10 | Five Immunovant insiders (CFO, COO, CTO, CLO, and a director) sold a combined $2.85M in open-market shares on June 26, 2 | Jun 26, 2026 |
| IONS | CLUSTER | neutral | 2/10 | CEO Monia Brett P and EVP Research Eric Swayze sold a combined ~$7.7M in open-market sales over a 3-day window, primaril | Jun 26, 2026 |
| KYMR | CLUSTER | bearish | 6/10 | A significant insider selling cluster at Kymera Therapeutics, led by director BVF Partners' $89.2M open-market sale, tot | Jun 26, 2026 |
| IMVT | 144 | neutral | 4/10 | Tiago Girao, an officer of Immunovant, filed a Form 144 indicating intent to sell 10,000 shares (~$384,640 at filing) vi | Jun 26, 2026 |
| ALXO | 8-K | neutral | 5/10 | ALX Oncology entered into a $50M secured term loan facility with HSBC Ventures, drawing $10M at closing to refinance exi | Jun 26, 2026 |
| SNGX | 424B5 | bearish | 7/10 | Soligenix, Inc. filed a 424B5 prospectus supplement to increase the maximum dollar amount of common stock it can sell un | Jun 26, 2026 |
| CERO | 8-K | bearish | 6/10 | CERO Therapeutics entered into an amended and restated convertible promissory note with SRX Health Solutions, providing | Jun 26, 2026 |
| AQST | S-3 | neutral | 6/10 | Aquestive Therapeutics filed an S-3 shelf registration statement, but the primary event in this filing is the entry into | Jun 26, 2026 |
| VXRT | 8-K | mixed | 5/10 | Vaxart entered Modification No. 7 to its BARDA Project Agreement, reducing total available funding by ~$116M to ~$345M f | Jun 26, 2026 |
| CELZ | S-1/A | bearish | 6/10 | Creative Medical Technology Holdings (CELZ) filed Amendment No. 1 to its S-1 for a best-efforts public offering of up to | Jun 26, 2026 |